News | May 30, 2012

Acquisition Strengthens Maquet's Suite of Products for Extracorporeal Life Support

May 30, 2012 — MAQUET Cardiopulmonary, a business unit of MAQUET Cardiovascular and a leader in extracorporeal membrane oxygenation (ECMO) and extracorporeal life support (ECLS) systems, announced that it has signed an agreement with Avalon Laboratories to acquire its Avalon Elite Bi-Caval dual lumen catheter and complimentary vascular access kits for use during ECMO and ECLS.

"It was our cardiopulmonary business unit which started a paradigm shift in moving extracorporeal life support into routine medical practice, most notably through the introduction of new products such as CARDIOHELP. Through the acquisition of the most advanced double lumen cannula we finally provide our customers a complete range of best in class products from tip to tip," said Christian Keller president and CEO of MAQUET Cardiovascular.

"The acquisition of the Bi-Caval dual lumen catheter complements our existing cardiopulmonary product line and strengthens our position as a leading global provider of ECMO and ECLS technologies," said Wolfgang Rencken, M.D., president and CEO of MAQUET Cardiopulmonary AG. "This product acquisition is just another example of our commitment to providing our customers with the most innovative and highest quality products available to treat critically ill patients."

"MAQUET's growing leadership in the cardiopulmonary space makes our Bi-Caval dual lumen catheter the ideal acquisition to further expand the number of patients globally who can benefit from this device," said Michael Janish, CEO of Avalon Laboratories.

The patented Avalon Elite Bi-Caval dual lumen catheter is indicated for simultaneous venous drainage and reinfusion of blood via the internal jugular vein during extracorporeal life support procedures. The catheter is designed to increase the efficiency of blood gas exchange by draining blood from both the upper and lower body while simultaneously re-infusing it directly into the heart. The catheter is also designed to minimize recirculation and maximize blood flow while providing a less invasive solution for patients. The Avalon Elite Bi-Caval dual lumen catheter has received 510(k) clearance from the U.S. Food and Drug Administration and the CE Mark from the European Medicines Agency.

The Avalon Elite Bi-Caval dual lumen catheter rounds out MAQUET's cannula product line which also includes the state-of-the-art HLS single lumen cannula line and conventional double lumen pediatric cannulae. The Avalon Elite product range will be available via the MAQUET global sales and distribution channels as well as through existing Avalon distributors and will be sold under the trademark Avalon Elite.

"With the addition of the Avalon Elite catheter line, we now offer the customers and patients we serve with a full range of minimally invasive venous or arterial cannulation techniques for ECMO and ECLS," said Rencken. "The Avalon Elite Bi-Caval Dual Lumen Catheter is a state of the art ECMO/ECLS technology that sets the standard for new MAQUET catheter offerings in the future and will play an integral role in new cardiopulmonary offerings from MAQUET."

For more information: http://www.maquet.com

Related Content

Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
BTG Acquires Roxwood Medical
News | Business| October 05, 2017
BTG plc announced it has acquired Roxwood Medical, provider of advanced cardiovascular specialty catheters used in the...
TVA Medical Receives CE Mark for Next-Generation EverlinQ 4 EndoAVF System
News | Vascular Access| October 04, 2017
TVA Medical Inc. announced that its everlinQ 4 endoAVF System has received CE Mark in the European Union. The...
Reflow Medical's Wingman Crossing Catheter Receives FDA Clearance for Coronary Indication
News | Catheters| October 02, 2017
October 2, 2017 — Reflow Medical Inc. announced that the company has received 510(k) clearance from the U.S.
Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery| September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery| September 08, 2017
September 8, 2017 — ClearFlow Inc.
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
CMS Awards New Technology Add-on Payment for Perceval Sutureless Aortic Heart Valve
News | Heart Valve Technology| August 22, 2017
August 22, 2017 — LivaNova PLC announced its Perceval ...
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
Overlay Init